 Vaccibody AS and Nektar Therapeutics NASDAQ: NKTR today announced that the first patient has been dosed in the combination therapy of the Phase 12a study evaluating bempegaldesleukin bempeg, Nektars CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibodys personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck SCCHN. 